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Abstract: Chronic pain could be considered as a neurological disorder. Therefore, appropriate 
selection of the therapy, which should consider the pathophysiological mechanisms of pain, 
can result in a successful analgesic outcome. Tapentadol is an analgesic drug which acts both 
as a μ-opioid receptor (MOR) agonist and as a noradrenaline reuptake inhibitor (NRI), thereby 
generating a synergistic action in terms of analgesic efficacy, but not for the burden of adverse 
effects. Therefore, tapentadol can be defined as the first “MOR-NRI” drug. This molecule holds 
the potential to address at least some of the current limitations of analgesic therapy due to its 
unique mechanism of action and has shown to be safe and effective in the treatment of chronic 
pain of cancer and noncancer etiologies including nociceptive, neuropathic and mixed pain. In 
particular, the MOR component of tapentadol activity predominantly allows for analgesia in 
nociceptive pain; on the other hand, the NRI component contributes, now in a predominant 
manner, for analgesic efficacy in cases of neuropathic pain states. This paper will discuss 
recent pieces of evidence on the pathophysiology of pain, the background on tapentadol and 
then present some new studies on how the unique mechanism of action of tapentadol provides 
a key role in its analgesic efficacy in a number of pain states and with a favorable safety profile.
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Introduction
Chronic pain results from a maladaptive functional and structural transformation of 
neural circuits occurring over time at peripheral and central sites in the neural pathways 
from peripheral nerves to higher centers.1 Therefore, if the selection of the therapy 
takes into account the pathophysiological mechanisms of pain, a successful analgesic 
outcome is more likely.
It is widely accepted that the neurobiological modifications occurring in chronic 
pain can be major contributors to the poor efficacy shown by analgesic therapy.2,3 
Moreover, available analgesic options are not always applied in accordance with the 
growing understanding of the mechanisms underlying both acute pain and the transition 
processes leading to chronic pain.1 It is generally accepted that pain can be divided 
into nociceptive (generally pain arising from inflammatory processes due to tissue 
damage), neuropathic (arising from a lesion or disease of the somatosensory nervous 
system), and mixed pains such as low back pain and cancer pains where both types of 
pain can co-exist. Importantly, analgesics acting at the periphery have to be targeted 
to the type of pain – NSAIDs for nociceptive pains or ion channel modulators for 
neuropathic pain, whereas centrally acting drugs may have much broader indications.4
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Tapentadol acts both as a μ-opioid receptor (MOR) ago-
nist and as a noradrenaline (NA) reuptake inhibitor (NRI), 
thereby generating synergistic analgesic action.5–7 The 
elevated NA at spinal synapses leads to inhibition of pain 
signaling through activation of the inhibitory post-synaptic 
α-2 adrenoceptor on spinal nociceptive neurones, an action 
that mimics activity in certain descending inhibitory path-
ways from brain to spinal cord. Tapentadol, therefore, can 
be defined as a “MOR-NRI” drug. This molecule holds the 
potential to address at least some of the current limitations 
of analgesic therapy in terms of mechanism of action and 
has shown to be safe and effective in the treatment of several 
types of chronic pain, including nociceptive, neuropathic, 
mixed and cancer pains.8,9
Here we discuss, in the light of mechanisms contribut-
ing to the pathophysiology of pain, how the novel mecha-
nism of action of tapentadol forms a basis for analgesic 
efficacy in nociceptive, neuropathic and mixed pains with 
a reduced side-effect profile compared with classical MOR 
agonists.
Pathophysiology of pain: new 
evidence
The importance of central sensitization
According to standard classifications, pain can be distin-
guished into nociceptive pain (originating in tissues in 
response to nociceptor stimulation) and neuropathic pain, 
which originates in the peripheral or central nervous system 
following a lesion or disease to sensory nerve fibers.1 In both 
cases, nociceptive impulses propagate along thinly myelin-
ated A-delta and unmyelinated C-fibers, first-order peripheral 
nociceptive neurons and are then transmitted to second-order 
neurons in the spinal cord dorsal horn (Figure 1). In turn, 
these neurons that integrate and modulate the incoming sen-
sory information, transmit ascending pain messages via the 
thalamus to cortical sensory areas where both the intensity 
and location of pain are determined. Pathways from the spinal 
cord to the limbic brain lead to the aversive and threatening 
nature of the stimulus. Activity in these higher centers allows 
for the patient to build up their personal pain experience.
Figure 1 Ascending and descending pathways involved in pain transmission and modulation.
Note: Reproduced with permission from Coluzzi F, Fornasari D, Pergolizzi J, Romualdi P. From acute to chronic pain: tapentadol in the progressive stages of this disease 
entity. Eur Rev Med Pharmacol Sci. 2017; 21(7):1672–1683.1
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The transmission of noxious stimuli along the ascending 
pathways is influenced by the action of descending modula-
tory pathways. These pathways, especially at the spinal cord 
level, may modify the intensity and characteristics of the 
perceived pain. In particular, at spinal synapses, the descend-
ing pathways promote the release of several mediators, 
including endogenous opioids, NA, serotonin (5-HT) and 
γ-aminobutyric acid (GABA), which modulate the transmis-
sion between primary and secondary neurons.1
As recently reviewed, over the last few years mounting 
attention has been paid to the processes that lead to chronic 
pain, which encompasses a number of functional and struc-
tural modifications of the involved structures.10 Indeed, from 
the very early stage of acute pain (few hours), the neural 
structures involved in pain start to undergo plastic modifica-
tions so that peripheral and central sensitization can ensue. 
Tissue damage or nociceptor activation can lead to peripheral 
sensitization: peripheral nociceptors reduce their activation 
threshold and increase their responsivity to noxious stimuli. 
If the cause of the inflammatory pain resolves within a few 
days, such plastic modifications also regress.1,10 In cases of 
neuropathic pain, abnormal impulses in damaged and undam-
aged nerves as a result of altered ion channel activity and 
expression are sent to the spinal cord.1 In both cases, if the 
stimulus persists, high-frequency transmission is upheld with 
massive spinal release of glutamates and neuro-modulating 
peptides. This release of neurotransmitters ultimately leads 
to modifications of the spino-thalamic neurons and inter-
neurons, promoting increased excitability, a phenomenon 
known as central sensitization. Central sensitization may 
also involve other supraspinal integration structures, such as 
the thalamus and cortex, further promoting the transition to 
chronic pain.11 These modifications are mainly of functional 
nature (eg, enhanced activity of single neurons, recruitment of 
silent synapses and synaptic reinforcement) and are reversible 
in most cases.12 In this context, persistence of the peripheral 
nociceptive input and the reduction in the efficacy of some 
spinal inhibitory systems (eg, the GABAergic system) may 
also participate in the changes that lead to pain becoming 
chronic. In many studies on nociceptive and neuropathic pain 
models, the failure of descending inhibitory systems from 
the brain to spinal cord represents a key contributor to the 
enhanced pain condition.13
Importantly, understanding peripheral and central sensiti-
zation and the changes in descending systems may promote 
improved diagnosis and tailoring of treatment in patients with 
chronic pain, as well as the development of new regimens 
for mechanism-based therapy. Some of the mechanisms 
underlying these changes in pain processing can be translated 
from animals to humans providing new options in design of 
therapies and profiling drugs under development.
Pain evolution
According to available evidence, the process of chronifica-
tion of pain could be divided into three consecutive stages.1,14 
The first stage, acute pain, is characterized by localized 
pain, with intensity proportional to the stimulus or tissue 
damage. The pain usually resolves rapidly and often with 
anti-inflammatory drugs; lack of modulation of such episodes 
must not be underestimated, since they may ultimately trigger 
the more progressive stages. Noteworthy, neuropathic pain 
may take longer to become established as a lesion or disease 
causing the damage and dysfunction of the affected nerves 
develops. Neuropathy leads to numbness as nerves become 
disconnected from their peripheral targets but a significant 
number of patients have pain that may be ongoing or evoked, 
superficial or deep and described using particular sensations 
such as shooting, burning, electric-shock like, all indicative 
of abnormal nervous conduction.
In the second stage, defined as “progressive recurrent 
pain”, the pain has not yet become chronic. However, more 
frequent and intense episodes of pain may occur, with the 
interval between them being either entirely pain-free or 
characterized by mild persistent pain; central sensitization 
and altered descending control phenomena start developing 
leading to expanded areas of pain and more hyperalgesia 
and allodynia, and possibly even structural modifications 
may occur if pain is not adequately treated. This type of pain 
is likely responsive to effective treatment, and therefore the 
early establishment of appropriate therapy is of paramount 
importance.
In the third and final stage, the changes in the processes 
of pain have become established in the periphery, spinal cord 
and higher centers and both transmission and modulation 
pathways now may present pathological properties with a 
gain of excitation and a loss of inhibition. With increasing 
complexity, the pain becomes more difficult to control and 
stabilize. In clinical practice, it is paramount to attempt to 
recognize each stage and establish appropriate treatment as 
early as possible with the aim to prevent the progression of 
pain to a chronic state. In this phase, central sensitization 
and other changes becomes more and more established, con-
tributing to a number of different pain conditions (Table 1). 
Moreover, as pain becomes chronic, quality of life reduces, 
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and the patients may experience mood alterations, depres-
sion and/or anxiety, and diminished ability to carry out daily 
activities.1,10
Crucial role of descending pathways
Descending facilitatory and inhibitory pathways originat-
ing in supraspinal centers could influence the perception of 
pain and modulate the activity of spinal nociceptors through 
increased or decreased propagation of signals to the brain.13,15 
The release of neurotransmitters, including endogenous opi-
oids, NA and 5-HT, underlies the modulation of the noxious 
stimulus.
MOR agonists inhibit transmission of pain signals along 
the ascending pathways and are involved in the modulation 
of supraspinal pain signals through their action in descend-
ing pathways.1,16 Noradrenergic pathways exert an inhibi-
tory effect on the transmission of acute pain, and changes 
in these systems appear to contribute to chronic pain.17 
Conversely, serotoninergic pathways may have a facilitatory 
effect particularly in the advanced stages of chronicity and 
are, therefore, pro-nociceptive.13,18 An imbalance between 
amplified spinal ascending signals and inadequate activation 
of the descending inhibitory pathways has been suggested to 
lead to the development and maintenance of many chronic 
pain syndromes.13
Experimental evidence suggests that effective involve-
ment of inhibitory descending pathways could protect against 
the development of chronic pain.19 Moreover, the MOR 
activation is particularly relevant in acute nociceptive pain, 
while the inhibition of NA reuptake activity plays a crucial 
role in chronic neuropathic pain.20
A number of analgesic drugs can either interact with or 
have their actions modulated by these systems, reinforcing 
their importance in the establishment of pain, but also in its 
control. However, until recently, a molecule endowed with 
the ability to restore physiological balance between ascend-
ing and descending pathways was not available in clinical 
practice.21
Pharmacology of tapentadol
Mechanism of action
Tapentadol is a novel, centrally acting analgesic drug. It is 
the first representative of a new class of drugs, which can be 
referred to as MOR-NRI drugs, and it displays an analgesic 
efficacy comparable or superior to that of strong classical 
opioids such as oxycodone and morphine.5,6,22,23 Notewor-
thy, this molecule was synthetized by a rational drug-design 
program aimed at defining a molecule characterized by both 
MOR and NRI activity.6,21 Despite a 50-fold lower affinity 
for MOR and relatively moderate NRI activity (Ki =0.48 μM 
for rat synaptosomal uptake inhibition) tapentadol potency 
is comparable to that of morphine across a variety of pre-
clinical pain models.24 As previously documented,25 such 
potency cannot be explained by a simple additive effect, but 
rather by a synergistic interaction between the two distinct 
mechanisms of action within the single molecule. Thanks 
to this intricate interaction and mutual enhancement of the 
individual effects, relatively moderate receptor activities are 
sufficient for both mechanisms of action to achieve a strong 
analgesic effect by acting on both ascending and descending 
pathways (Figure 2). Importantly, the two mechanisms do not 
interact synergistically on the burden of adverse effects.6,26 
Remarkably, a very recent study suggested that the “μ-load” 
of tapentadol is ≤40%, relative to pure MOR agonists, which 
have, by definition a μ-load of 100%.27 This reduced μ-load 
likely translates into a more favorable tolerability profile of 
tapentadol compared with strong classical opioids. Moreover, 
tapentadol shows minimal serotoninergic activity.28 This 
pharmacological profile may have importance in chronic 
therapy, since the activation of serotoninergic pathways 
produce pro-algesic effects and may also stimulate emesis 
Table 1 Chronic pain conditions in which different aspects of 
the central sensitization phenomenon have been assessed and 
validated mechanistically with quantitative sensory testing
Chronic fatigue syndrome
Chronic low back pain
Chronic pancreatitis
endometriosis
Fibromyalgia
irritable bowel syndrome
Migraine
Multiple chemical sensitivity
Myofascial pain syndrome
Neurogenic pain
Non-cardiac chest pain
Osteoarthrosis
Pelvic pain/interstitial cystitis
Post-traumatic stress disorder
Postoperative chronic pain
Primary endometriosis/dysmenorrhea
Restless legs
Rheumatoid arthritis
Shoulder impingement syndrome
Temporomandibular disorders
Tension type headache/chronic tension type headache
vulvodynia
whiplash
Note: Data from Arendt-Nielsen et al.10
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over time.13,18 The potential synergic effect of tapentadol has 
also been preliminarily assessed.29,30
experimental evidence
Some previous experimental evidence is worth consideration. 
Tapentadol has been demonstrated to partially retain its 
analgesic efficacy in knockout mice with a genetic deletion 
of MOR,31 thus confirming the relevance of its noradrenergic 
component for pain relief. Using in vivo electrophysiological 
tests in spinal nerve ligated and sham-operated rats, systemic 
tapentadol dose-dependently reduced evoked responses of 
spinal dorsal horn neurons to a range of peripheral stimuli.32 
Moreover, spinal application of opioid receptor or selec-
tive α-2-adrenoceptor antagonists produced near complete 
reversal of the inhibitory effects of tapentadol, thus suggest-
ing that no mechanisms other than MOR-NRI is involved 
in tapentadol-induced analgesia. In another animal study, 
the effects of systemic morphine, tapentadol or duloxetine 
were evaluated in rats with spinal nerve ligation (SNL) or 
sham surgery.33 Response thresholds to von Frey filament 
stimulation decreased significantly from baseline in SNL, and 
not in sham rats. All molecules produced reversal of tactile 
hypersensitivity. In more detail, duloxetine increased spinal 
CSF NA levels in both sham and SNL rats, but no significant 
differences were observed in animal groups. Tapentadol 
induced a significant increase in spinal NA levels in SNL, 
but not in sham, rats. At a higher dose, tapentadol increased 
spinal CSF NA levels in both SNL and sham groups; however, 
spinal NA levels were elevated for an extended period in SNL 
rats. This could be detected rapidly following tapentadol in 
both sham and SNL groups. On the other hand, morphine 
reversed tactile hypersensitivity in nerve-injured rats, but 
CSF NA levels were significantly reduced after MOR agonist 
administration in both sham and SNL rats. Overall, these 
data suggest that, in a model of experimental neuropathic 
pain, tapentadol and not morphine, induces enhanced spinal 
NA levels, thus offering a mechanistic correlate to observed 
clinical efficacy and side-effect profiles in this pain state and 
a clear differentiation between a pure MOR and MOR-NRI. 
Indeed, NA is a key transmitter in descending inhibitory 
controls and in many pain conditions, the balance between 
central inhibitory NA and excitatory 5HT actions shifts lead-
ing to a gain of pain facilitation.13
In another study in a rat model, the acute effects of tapen-
tadol in the locus coeruleus (LC), a central nucleus, which is 
critical in pain modulation and is regulated by the noradrener-
gic and opioid systems were investigated.34 Overall, tapentadol 
inhibited the spontaneous electrophysiological activity of LC 
neurons in a dose-dependent manner. This inhibitory effect 
was reversed by both α-2-adrenoceptor antagonists and MOR 
antagonists. Furthermore, tapentadol inhibited LC response 
to mechanical stimulation in a  dose-dependent manner. Thus, 
Figure 2 Tapentadol: mechanism of action at spinal level.
Abbreviations: MOR, μ-opioid receptor; NRi, noradrenaline reuptake inhibitor; NA, noradrenaline; TAP, tapentadol. 
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acute administration of tapentadol inhibits LC neurons in vivo, 
mainly due to the activation of α-2-adrenoceptors; moreover, 
these data further confirm that both the noradrenergic and 
opioid systems participate in the inhibitory effect of tapentadol 
on LC neurons, accounting once again for the potent analgesic 
effect of tapentadol and its mild opioidergic side effects.
In a model of cancer pain, tapentadol administration 
resulted in marked inhibitions of the neuronal activity with 
efficacy against mechanical, thermal and electrically evoked 
activity.35 The effects of tapentadol were fully reversible 
by the MOR antagonist naloxone and partly by the α-2-
adrenoceptor antagonist atipamezole, again supporting the 
idea of MOR-NRI synergistic actions.
Last, tapentadol seems to be protective of splenic cyto-
kines differing from morphine, which exerts a generalized 
suppression on all cytokines.36
Human studies
Niesters et al38 investigated the influence of tapentadol on 
conditioned pain modulation (CPM; the human counterpart 
of diffuse noxious inhibitory controls), a descending inhibi-
tory system that uses NA and subsequent activation of the 
α-2-adrenoceptor37 and offset analgesia (OA, a test in which 
a large amount of analgesia becomes apparent upon a slight 
decrease in noxious heat stimulation).38 In total, 24 patients 
with diabetic polyneuropathy (DPN) were randomly assigned 
to either tapentadol prolonged release (PR) or placebo for 
4 weeks. Before treatment, no patient showed CPM or OA 
responses. At 4 weeks, CPM was significantly activated 
by tapentadol PR compared with placebo (24.2 vs 14.3%; 
P<0.001); relief of DPN pain was also greater in patients 
on tapentadol compared with placebo (P=0.028). On these 
bases, the authors of the study concluded that the analgesic 
effect of tapentadol in patients with DPN is dependent on the 
activation of descending inhibitory pain pathways. This back 
translates perfectly to the preclinical data that also shows a 
restoration of diffuse noxious inhibitory controls in neuro-
pathic models by the drug. Most importantly, this preclinical 
study revealed that diffuse noxious inhibitory control was an 
NA-mediated descending inhibition that is lost in a model of 
neuropathic pain. Thus, the ability of tapentadol to restore 
CPM is a perfect translation from the preclinical to clinical 
domain and moreover, such clinical data are in line with the 
NRI-mediated analgesic component of the drug.37
implications for clinical practice
According to the above-mentioned evidence, tapentadol has 
been described as “one key for two locks,” since this molecule 
presents a chemical structure that can simultaneously interact 
with both the opioidergic and the noradrenergic systems.39 
This synergistic action represents an important option for the 
first-line treatment of patients who require both nociceptive 
and neuropathic pain relief (and therefore also mixed pains), 
also given its favorable efficacy/side-effect ratio.40 In particu-
lar, the inhibition of NA reuptake is a key mechanism – and 
may even predominate over opioid actions – in chronic pain 
states, and especially neuropathic ones, thus reinforcing 
the notion that tapentadol is markedly different to classical 
opioids.21 Moreover, the reduced incidence of some typical 
opioid-induced side effects, compared with equi-analgesic 
doses of classical opioids, further differentiate tapentadol 
from opioids.
Pharmacokinetic properties of 
tapentadol
Tapentadol follows a linear pharmacokinetics model. Oral 
adsorption is rapid with Cmax usually reached in less than 
2 hours and with a t1/2 of about 4 hours. Since tapentadol is 
not a prodrug, both its pharmacokinetics and analgesic effi-
cacy are independent of metabolic activation and individual 
variations among single patients. None of the metabolites 
of tapentadol have analgesic activity. Moreover, given its 
metabolism (which is mainly glucuronidation-based), this 
molecule is associated with a low risk of drug–drug interac-
tions at the cytochrome (CYP) 450 level, and may therefore 
be used in poly-treated patients.39 For this reason, tapentadol 
and its metabolites are almost completely (99%) eliminated 
in the urine.41 Therefore, tapentadol should be administered 
with caution in patients with severely impaired renal function.
In an investigation on the PR formulation, Zannikos et 
al42 evaluated the pharmacokinetics of tapentadol adminis-
tered to healthy subjects enrolled in seven different studies. 
Overall, maximal tapentadol serum concentrations (Cmax) 
were observed 5 hours after dosing. Mean terminal half-life 
ranged from 4.4 to 5.9 hours. Tapentadol Cmax and AUC 
values increased following single PR doses of 50–250 mg. 
Tapentadol concentrations increased during repeat dosing and 
reached the steady-state by the third dose. Coadministration 
of the 250 mg dose with a high-fat meal increased Cmax 
and AUC values by less than 17%, thus supporting the use 
of tapentadol PR without regard to food intake.
Conclusion
The pharmacological profile of tapentadol, combining syner-
gistically MOR agonism and NRI in one molecule, appears to 
be unique and it seems reasonable to propose for tapentadol 
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a new class of centrally acting analgesics, designated MOR-
NRI.5 The drug that was developed through a rational drug-
design program is characterized by a synergistic MOR-NRI 
action as shown by multiple biochemical, pharmacological, 
behavioral and electrophysiological studies in animals. This 
promotes two forms of inhibition, which allows the restora-
tion of the physiological balance within ascending (MOR 
action) and descending (NRI action) pathways implied in 
the pathophysiology of chronic pain. Remarkably tapentadol 
showed to have only 40% of μ-load compared with a classical 
opioid at equianalgesic concentration. This reduced μ-load is 
the result of the combination and synergistic interaction of 
the two MoAs with regards to analgesia. Due to this, lower 
opioid activity is needed to reach comparable analgesia and 
as a result a more favorable tolerability profile is achieved.
Translation of experimental evidence to patients is a 
crucial issue in pain research. For tapentadol the experi-
mental evidence that NRI is a key mechanism that can be 
predominant in chronic/neuropathic pain, reinforces the 
concept that tapentadol is different to classical opioids 
and may therefore be an a priori choice for the treatment 
of chronic, neuropathic and mixed pain.21 This concept has 
been strengthened and expanded to other drugs (tramadol, 
buprenorphine, loperamide, cebranopanol) by Raffa et al27 
and Pergolizzi et al.43 They state that the categorization of 
all analgesics that have any component of opioid mechanism 
of action into the same class is anachronistic and mislead-
ing; recognition of subclasses of opioids seems warranted 
scientifically and beneficial to healthcare providers, payers 
and regulators.27,43
Remarkably, through its NRI mechanism, tapentadol 
restores descending NA inhibitory controls in animals and 
patients, a rare insight into the mechanistic actions of a drug 
in humans. In all, tapentadol revitalizes central modulation 
of pain. The broad effectiveness of tapentadol for nocicep-
tive, neuropathic and mixed pains, due to its combination 
of MOR agonism and NRI activity, may simplify chronic 
pain treatment by eliminating the need to isolate and treat 
the individual types of chronic pain with a combination of 
different analgesics. Thanks to its low risk of pharmaco-
kinetic interactions, tapentadol may also facilitate chronic 
pain management in poly-medicated patients, including 
elderly patients.
Key points
•	 Tapentadol is the first, and so far, unique agent of a novel 
class of analgesic agents, and was developed through a 
rational drug-design program.
•	 This molecule is characterized by a synergistic MOR-NRI 
action, allowing the physiological balance to be restored 
between ascending (MOR action) and descending (NRI 
action) pathways implied in the pathophysiology of 
chronic pain.
•	 Remarkably, the MOR component accounts only for 40% 
of the total: this reduced μ-load is the result of the combi-
nation and synergistic interaction of the two MoAs with 
regards to analgesia and may result in a more favorable 
tolerability profile.
•	 This peculiar mechanism of action suggests that tapen-
tadol may be useful in patients with nociceptive, neuro-
pathic and mixed pain.
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